Payment overview · 2025
General Payments
$306.41
6 reported records · 5 companies
Healthcare provider profile · identity verified
Lev J Paukman, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BROOKLYN, NY · NPI 1659475267
Verified facts
What the public records show
CMS Open Payments records show Lev J Paukman, MD received $306.41 in general payments during 2025 across 6 reported records.
Baxter Healthcare accounted for 61.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Baxter Healthcare | Unresolved — no canonical attribution shown | $188.63 | 61.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.54 | 14.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.79 | 8.4% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $23.97 | 7.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.48 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $188.63 | 1 |
| Food and Beverage | $117.78 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Hillrom - CP 150 Resting Electrocardiograph Normalized: hillrom cp 150 resting electrocardiograph |
Device | Baxter Healthcare | $188.63 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.54 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $25.79 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 127 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 472 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 292 | 45 |
| Metformin Hcl | Metformin Hcl | 290 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 290 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 43 |
| Omeprazole | Omeprazole | 203 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 155 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 23 |
| Clonidine Hcl | Clonidine Hcl | 144 | 37 |
| Gabapentin | Gabapentin | 130 | 26 |
| Eliquis | Apixaban | 127 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 123 | 25 |
| Ozempic | Semaglutide | 119 | 21 |
| Alprazolam | Alprazolam | 114 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 22 |
| Furosemide | Furosemide | 112 | 34 |
| Montelukast Sodium | Montelukast Sodium | 107 | 21 |
| Azithromycin | Azithromycin | 89 | 60 |
| Linzess | Linaclotide | 89 | 13 |
| Clonazepam | Clonazepam | 88 | 12 |
| Ibuprofen | Ibuprofen | 88 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 19 |
| Dexilant | Dexlansoprazole | 79 | suppressed |
| Simvastatin | Simvastatin | 76 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 16 |
| Glipizide | Glipizide | 71 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 71 | suppressed |
| Finasteride | Finasteride | 68 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | suppressed |
| Lisinopril | Lisinopril | 67 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 12 |
| Glipizide Er | Glipizide | 64 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 13 |
| Meclizine Hcl | Meclizine Hcl | 61 | 15 |
| Jardiance | Empagliflozin | 59 | 14 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 57 | suppressed |
| Lidocaine | Lidocaine | 55 | suppressed |
| Meloxicam | Meloxicam | 55 | suppressed |
| Nifedipine Er | Nifedipine | 53 | 12 |
| Vascepa | Icosapent Ethyl | 53 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Famotidine | Famotidine | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 21 |
| Glimepiride | Glimepiride | 51 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 51 | suppressed |
| Creon | Lipase/Protease/Amylase | 50 | suppressed |
| Hydrocortisone | Hydrocortisone | 50 | 23 |
| Carvedilol | Carvedilol | 48 | 11 |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Allopurinol | Allopurinol | 45 | suppressed |
| Chlorthalidone | Chlorthalidone | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 11 |
| Tramadol Hcl | Tramadol Hcl | 41 | 16 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 39 | suppressed |
| Diazepam | Diazepam | 38 | 12 |
| Spironolactone | Spironolactone | 38 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Livalo | Pitavastatin Calcium | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Procto-Med Hc | Hydrocortisone | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Anastrozole | Anastrozole | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Cozaar | Losartan Potassium | 22 | suppressed |
| Ursodiol | Ursodiol | 22 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Atenolol | Atenolol | 19 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | suppressed |
| Norvasc | Amlodipine Besylate | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Digoxin | Digoxin | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Dotti | Estradiol | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Qbrexza | Glycopyrronium Tosylate | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $306.41 · 6 records | Baxter Healthcare | BREZTRI, ELIQUIS, Hillrom - CP 150 Resting Electrocardiograph, NURTEC ODT, SUBLOCADE, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error